Clinical trial Recruiting at 1 site Interventional Ages 6 to 17

GlycoQuest: an AI-powered CGM game for kids with type 1 diabetes and their families

Official title: GlycoQuest: Glycemic and Psychosocial Outcomes of a CGM-Integrated, AI-Adaptive Serious Game Digital Therapeutic in Newly Diagnosed Pediatric Type 1 Diabetes: A Parallel-Group Randomized Controlled Trial

Run by Shifa International Hospital · NCT07726680 · Data updated 2026-11-12

A CGM-linked, AI-adaptive serious game is tested with children 6-17 who have type 1 diabetes and their primary caregivers to see if it helps with glucose control and coping in the first year after diagnosis.

More Type 1 Diabetes Mellitus (T1DM) trials

Quick facts

Study typeInterventional
Ages6 Years to 17 Years
SexAll
Enrollment110 (estimated)
SponsorShifa International Hospital
Academic / other
Locations1 site (Lahore, Punjab Province)
StatusRecruiting
StartedJune 1, 2026
Main results expectedNovember 1, 2026
Study endsNovember 30, 2026
Registry record updatedJuly 24, 2026
Trial IDNCT07726680 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children and adolescents aged 6-17 with a recent type 1 diabetes diagnosis (within 3 months) and a willing primary caregiver, who currently use or will start CGM and have access to a compatible device.

Probably not a fit

Children without CGM access or with conditions preventing engagement in a digital therapeutic may not receive benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial tests GlycoQuest, a digital therapeutic that blends continuous glucose monitoring data with an adaptive, child-facing game and parent–child collaboration. The game uses real-time glucose patterns to tailor learning pathways and in-game scenarios, aiming to improve self-management skills and reduce diabetes distress. The study also includes psychosocial content addressing fear of hypoglycemia, stigma, illness acceptance, and family communication, along with practical modules on insulin safety and carbohydrate estimation. Participants are children with recent type 1 diabetes diagnosis (within 3 months) and their primary caregivers, who will engage with the CGM-linked platform over the first year after diagnosis. The primary question is whether this personalized digital intervention can improve glycemic outcomes and family functioning compared with standard education alone.

Why it matters

Potential benefit: If successful, the intervention could improve time-in-range and reduce diabetes distress for patients and families during the critical first year after diagnosis.

How similar studies have gone: Previous digital therapeutics in pediatric diabetes have shown promise in improving engagement and knowledge, though AI-adaptive CGM-linked gaming is relatively novel and evidence is emerging.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Child or adolescent aged 6 to 17 years at enrollment.
* Diagnosis of type 1 diabetes confirmed by a pediatric endocrinologist according to standard clinical criteria.
* Type 1 diabetes diagnosed within the previous 3 months.
* Primary caregiver aged 18 years or older willing to participate as part of a parent-child dyad.
* Current use of continuous glucose monitoring or willingness to initiate CGM as part of standard diabetes care.
* Household access to a compatible smartphone or tablet, or willingness to use a study-provided device if available.
* Ability of child and caregiver to engage with study procedures and digital intervention content.
* Caregiver able to provide written informed consent.
* Child able to provide age-appropriate assent.

Exclusion Criteria:

* Type 1 diabetes diagnosed more than 3 months before enrollment.
* Concurrent participation in another intensive diabetes behavioral intervention trial.
* Significant developmental, intellectual, visual, motor, or psychiatric condition that, in the opinion of the clinical team, would preclude meaningful engagement with the digital game interface or study procedures.
* Acute psychiatric instability or safety concern requiring urgent specialist intervention.
* Planned transfer to a different diabetes care provider within 6 months.
* Absence of internet access that cannot be addressed by study support.

Where it's running

  • Shifa International hospital
    Lahore, Punjab Province, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.